ALK and neoplasm: Activation of the MEK pathway also contributes to ALK TKI resistance, mainly through deficiency/low expression of Wiskott–Aldrich syndrome protein (WASP) (68), a tumor suppressor whose loss leads to tumor development and invasion (69).